Although there is some evidence supporting Revlmid for non-Hodgkin’s Lymphoma, there is much less evidence for the Hodgkin’s variant. A recent phase II study in 38 patients with Hodgkin;s suggested that lenalidomide was well tolerated, and the most common grade 3/4 AEs were neutropenia (47%), anemia (29%), and thrombocytopenia (18%). Four patients discontinued lenalidomide because of rash, elevated transaminases/bilirubin, and cytopenias. It concluded that the study provides preliminary evidence of lenalidomide’s activity in patients with relapsed and refractory non-Hodgkin’s lymphoma, and therefore exploration of lenalidomide in combination with other active agents is warranted. Several other small studies have come to similar conclusions. Several phase II studies are exploring activity of lenalidomide by itself or in combination.
Chen C, Paul H, Xu W, et al. A phase II study of lenalidomide in previously untreated, symptomatic chronic lymphocytic leukemia (CLL). Blood. 2008;112:23, abstract number 44.
Kornblau SM, Burger JA, Ferrajoli A.et al, Lenalidomide (REVLIMID) as initial therapy of elderly patients with chronic lymphocytic leukemia.Blood. 2011 Jul 1.
Todd A. Fehnige et al, A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma Blood November 10, 2011 vol. 118 no. 19 5119-5125
Boris Bll et al, Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma, ritish Journal of Haematology Volume 148, Issue 3, pages 480482, February 2010
Sameer A. Batoo, The emerging role of lenalidomide in the management of lymphoid malignancies herapeutic Advances in Hematology February 2011 vol. 2 no. 1 45-53
For Lay version see here
For Revlmid in non-Hodgkin’s lymphoma see here
Revlimid for myelofibrosis, here